M. Gauthier

发表

Impact on overall survival of radioactive iodine in low-risk differentiated thyroid cancer patients.

D. Papathanassiou, F. Bonnetain, C. Schvartz, 2012, The Journal of clinical endocrinology and metabolism.

Natural Killer cells and monoclonal antibodies: two partners for successful antibody dependent cytotoxicity against tumor cells.

D. Bensoussan, M. Gauthier, C. Laroye, 2021, Critical reviews in oncology/hematology.

Absolute volume of the rectum and AUC from rectal DVH between 25Gy and 50Gy predict acute gastrointestinal toxicity with IG-IMRT in prostate cancer

P. Maingon, P. Walker, G. Créhange, 2016, Radiation oncology.

FOLFIRI.3 (CPT-11 plus folinic acid plus 5-FU) alternating with gemcitabine or gemcitabine (G) alone in patients (pts) with previously untreated metastatic pancreatic adenocarcinoma (MPA): Results of the randomized multicenter AGEO phase II trial FIRGEM.

F. Fein, F. Bonnetain, J. Taieb, 2012 .

Primary cardiac sarcomas: a retrospective study of the French Sarcoma Group.

N. Girard, J. Blay, F. Collin, 2014, European journal of cancer.

NOX2-dependent ATM kinase activation dictates pro-inflammatory macrophage phenotype and improves effectiveness to radiation therapy

E. Solary, F. Rosselli, E. Deutsch, 2017, Cell Death and Differentiation.

Mesenchymal Stem/Stromal Cell Production Compliant with Good Manufacturing Practice: Comparison between Bone Marrow, the Gold Standard Adult Source, and Wharton’s Jelly, an Extraembryonic Source

L. Reppel, D. Bensoussan, M. Gauthier, 2019, Journal of clinical medicine.

Chemotherapy of advanced small-bowel adenocarcinoma: a multicenter AGEO study.

I. Sobhani, J. Taïeb, F. Bonnetain, 2010, Annals of oncology : official journal of the European Society for Medical Oncology.

FOLFIRINOX for Locally Advanced Pancreatic Adenocarcinoma: Results of an AGEO Multicenter Prospective Observational Cohort

F. Carbonnel, J. Blanc, J. Taieb, 2014, Annals of Surgical Oncology.

Visceral fat area as a new independent predictive factor of survival in patients with metastatic renal cell carcinoma treated with antiangiogenic agents.

F. Ghiringhelli, S. Ladoire, F. Bonnetain, 2011, The oncologist.

Second‐line chemotherapy with fluorouracil, leucovorin, and irinotecan (FOLFIRI regimen) in patients with advanced small bowel adenocarcinoma after failure of first‐line platinum‐based chemotherapy

J. Taïeb, F. Bonnetain, D. Malka, 2011, Cancer.

Prognostic relevance at 5 years of the early monitoring of neoadjuvant chemotherapy using 18F-FDG PET in luminal HER2-negative breast cancer

C. Coutant, P. Fumoleau, F. Brunotte, 2014, European Journal of Nuclear Medicine and Molecular Imaging.

Sequential FOLFIRI.3 + Gemcitabine Improves Health-Related Quality of Life Deterioration-Free Survival of Patients with Metastatic Pancreatic Adenocarcinoma: A Randomized Phase II Trial

F. Fein, F. Bonnetain, J. Taieb, 2015, PloS one.

FOLFOX as second-line chemotherapy in patients with pretreated metastatic pancreatic cancer from the FIRGEM study

J. Taieb, T. Aparicio, M. Gauthier, 2014, BMC Cancer.

Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups

P. Maingon, G. Créhange, M. Gauthier, 2012, Radiation oncology.

Pathological complete response and survival according to the level of HER-2 amplification after trastuzumab-based neoadjuvant therapy for breast cancer

F. Penault-Llorca, P. Fumoleau, S. Ladoire, 2010, British Journal of Cancer.

Systematic Review on CAR-T Cell Clinical Trials Up to 2022: Academic Center Input

L. Reppel, D. Bensoussan, M. Gauthier, 2023, Cancers.

Fixed-dose rate gemcitabine alone or alternating with FOLFIRI.3 (irinotecan, leucovorin and fluorouracil) in the first-line treatment of patients with metastatic pancreatic adenocarcinoma: an AGEO randomised phase II study (FIRGEM).

J. Taïeb, F. Fein, F. Bonnetain, 2014, European journal of cancer.

Prognostic value of health-related quality of life in patients with metastatic pancreatic adenocarcinoma: a random forest methodology

F. Fein, F. Bonnetain, J. Taieb, 2016, Quality of Life Research.

Response shift effects on measuring post-operative quality of life among breast cancer patients: a multicenter cohort study

F. Guillemin, T. Conroy, F. Bonnetain, 2013, Quality of Life Research.

Image-guided IMRT for localized prostate cancer with daily repositioning: inferring the difference between planned dose and delivered dose distribution.

P. Maingon, A. Arnaud, F. Bonnetain, 2014, Physica medica : PM : an international journal devoted to the applications of physics to medicine and biology : official journal of the Italian Association of Biomedical Physics.

Early choline levels from 3-tesla MR spectroscopy after exclusive radiation therapy in patients with clinically localized prostate cancer are predictive of plasmatic levels of PSA at 1 year.

Alexandre Cochet, Franck Bonnetain, P. Maingon, 2011, International journal of radiation oncology, biology, physics.

Exclusive image guided IMRT vs. radical prostatectomy followed by postoperative IMRT for localized prostate cancer: a matched-pair analysis based on risk-groups

P. Maingon, G. Créhange, M. Gauthier, 2012, Radiation oncology.

Impact of Response Shift on Time to Deterioration in Quality of Life Scores in Breast Cancer Patients

F. Guillemin, T. Conroy, F. Bonnetain, 2014, PloS one.

Clinical impact of margin reduction on late toxicity and short-term biochemical control for patients treated with daily on-line image guided IMRT for prostate cancer.

Franck Bonnetain, P. Maingon, F. Bonnetain, 2012, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

NOX2-dependent ATM kinase activation dictates pro-inflammatory macrophage phenotype and improves effectiveness to radiation therapy

E. Solary, F. Rosselli, F. Milliat, 2017, Cell Death and Differentiation.